Board & Management
Ebba Fåhraeus, b. 1963. Chairman of the Board, elected 2018
MBA from the Stockholm School of Economics, Sweden. Fåhraeus is CEO of SmiLe Incubator in Lund, is a member of the boards of the Faculty of Medicine at Lund University, Arc Aroma Pure AB, Skandia's General Assembly and Coala Life. Fåhraeus has deep and wide experience in business development, growth strategies and marketing in both listed and non-listed life sciences companies.
Holdings in AcuCort: 15,134 shares.
Lennart Bruce, b. 1944. Director of the Board, elected 2011
Ph.D. in animal physiology, Lund University, Sweden. Bruce has 40 years in the pharmaceutical industry and has extensive experience in drug development. Bruce was one of the founders of Biovitrum and has started, and is now managing, Viken Pharma AB and Viken Pharma Consulting. Broad board experience from a number of biotech companies in several countries. Advisor to AQILION AB (legacy Partnerskap för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB).
Holdings in AcuCort: 117,333 shares and an additional 20,000 shares through Viken Pharma.
Anna Eriksrud, b. 1958. Director of the Board, elected 2017
International MBA from Uppsala University, Sweden. Eriksrud has a background as a health care entrepreneur with over 25 years of experience in the medical and pharmaceutical sector, primarily from Q-Med and Pharmacia. She has run her own business through Apoteksamariten and has leadership experience from international cross-functional teams, establishing new market categories and launching global brands both in Europe and the US. Eriksrud is CEO of NeoDynamics AB.
Holdings in AcuCort: 13,427 shares.
Alexandra Johnsson, b. 1971. Director of the Board, elected 2018
Master of Science in International Economics from Umeå University, Sweden. Johnsson has over 20 years of experience in marketing and sales in leading positions in both global and small-scale development companies. Most recent she held a position as the Nordic Marketing Manager for Zonnic's non-prescription nicotine products.
Holdings in AcuCort: 7,000 shares.
Göran Kvist, b. 1950. Director of the Board, elected 2013
Pharmacist, focusing in biochemistry, Uppsala University, Sweden. Kvist has long experience of international good manufacturing practice (GMP). Has served on the board of several companies, including CEO and Chairman of TQ Quality AB and Chairman and co-founder of QP Support AB, Dilafor AB and Modus Therapeutics AB. Kvist has held several QA and QC management positions within the Pharmacia and Ferring Groups, with global development projects and registered pharmaceuticals. Advisor to AQILION AB (legacy Partnerskap för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB).
Holdings in AcuCort: 75,000 shares through TQ Kvalitetskonsult.
Ann Gidner, b. 1966. CEO (interim) since 2020
Master’s degree in biotechnology from Lund University, Faculty of Engineering, and the French Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique and an MBA from Lund University. Her background in the pharmaceutical industry and life science includes senior positions as Head of the CTS Business Unit at Inceptua GmbH in Berlin, Licensing Director at Albumedix A/S (Novozymes Biopharma) and as CEO of the pharma strategy company Monocl AB. She has previous extensive experience of global commercial responsibility in large international CMO corporations. She has built the business model and created strong sales growth at Cambrex Corporation with placement in Sweden and New Jersey, USA, and at Saltigo GmbH with placement in Germany. Board member of SenzaGen AB since 2014.
Holdings in AcuCort: 7,767 shares.